Daiichi Sankyo To Acquire Plexxikon Inc.    “Building a world class oncology pipeline by 2015”                    March 1,...
Agenda1.Strategic Rationale2.Plexxikon’s Profile3.Financial Conditions                         1
Strategic Rationale 
Our Oncology StrategyBuilding a world class pipeline by 2015  Secure market presence  Accelerate proof‐of‐concept trial la...
Oncology Pipeline Collaborations                    Exploratory stage   Preclinical stage    Phase  I       Phase  II     ...
Robust Pipeline of Plexxikon                                                                         PhaseProducts bythera...
Plexxikon’s Technical ApproachScaffold Based Drug DiscoveryTM            Screening of “Scaffold” based library, followed b...
Global Research Structure                < Japan >                                 Daiichi Sankyo                         ...
Plexxikon’s Profile
Plexxikon at a Glance Established in 2001 Private company (not listed) Location:  Berkeley, CA CEO: K. Peter Hirth, Ph.D. ...
Plexxikon is an Attractive Opportunity   Talent/   networks                 Strong internal and external scientific talent...
The San Francisco Bay Area        Marin                               Solano                                              ...
About PLX4032 Initial target indication: metastatic melanoma                               expressing the BRAF mutation Cu...
Rights Obtained for PLX4032 Revenue is from running royalties Upon FDA approval, Daiichi Sankyo, Inc., will  co‐promote PL...
Financial Conditions
Financial ConditionsDaiichi Sankyo has agreed with Plexxikon’s shareholders to acquire all shares of Plexxikon Daiichi San...
Memo       15
Memo       15
Contact address regarding this material                  DAIICHI SANKYO CO., LTD.              Corporate Communications De...
Upcoming SlideShare
Loading in...5



Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. Daiichi Sankyo To Acquire Plexxikon Inc.  “Building a world class oncology pipeline by 2015” March 1, 2011 Joji Nakayama President and CEO Daiichi Sankyo Co., LTD.
  2. 2. Agenda1.Strategic Rationale2.Plexxikon’s Profile3.Financial Conditions 1
  3. 3. Strategic Rationale 
  4. 4. Our Oncology StrategyBuilding a world class pipeline by 2015 Secure market presence Accelerate proof‐of‐concept trial launches Accelerate market launches for new products and indications Reinforce pipelines with multiple new chemical entities (NCE) Enhance world class drug discovery capabilities and organization Undertake internal projects Secure external resources through in‐licensing and M&As Establish R&D capabilities and technological foundations to  underpin sustainable growth 3
  5. 5. Oncology Pipeline Collaborations Exploratory stage Preclinical stage Phase  I Phase  II Phase III Application ARQ 197Small molecules AKIPTM c‐MET inhibitor Scaffold-Based PLX3397 PLX4032 Drug DiscoveryTM FMS/KIT BRAF Efatutazone PPARγ Nimotuzumab Denosumab EGFR Ab RANKL AbAntibodies Innovative antibodies Alliance for antibody  Technology U3‐1565 U3‐1287 HB‐EGF Ab HER3 Ab Tigatuzumab DR5 Ab In‐house projects In‐licensed projects U3/Plexxikon projects 4
  6. 6. Robust Pipeline of Plexxikon PhaseProducts bytherapeutic area Indication Preclinical Phase 1 Phase 2 Phase 3Oncology PLX4032 Melanoma Colorectal Cancer PLX3397 Metastatic Breast CancerInflammation PLX5622 Rheumatoid Arthritis Kinase inhibitor Systemic Lupus ErythematosusCardio-renal Polycystic Kidney Kinase inhibitor Disease Protease inhibitor HypertensionCNS Kinase inhibitor Alzheimer’s Disease Kinase inhibitor Multiple Sclerosis 5
  7. 7. Plexxikon’s Technical ApproachScaffold Based Drug DiscoveryTM Screening of “Scaffold” based library, followed by high purity protein purification, and high throughput co-crystallography of drugs and targets ▪ Novel chemical space ▪ IP ▪ Small molecular weight ▪ Formulation components ▪ Targeting; selectivity vs. ▪ Precision chemistry potency ▪ Family of proteins ▪ Beyond oncology 6
  8. 8. Global Research Structure < Japan > Daiichi Sankyo Daiichi Sankyo RD Associe Asubio Pharma RCI* Global Development Plexxikon< India > < US > U3 Pharma < EU >* Daiichi Sankyo Life Science Research Centre in India  7
  9. 9. Plexxikon’s Profile
  10. 10. Plexxikon at a Glance Established in 2001 Private company (not listed) Location:  Berkeley, CA CEO: K. Peter Hirth, Ph.D.  Approximately 45 employees R&D areas:  Oncology, Inflammation, Cardio‐renal, CNS  9
  11. 11. Plexxikon is an Attractive Opportunity Talent/ networks Strong internal and external scientific talent Filing for EU and US marketing approval anticipated in  Market entry 2011  Commercial and Development partnership with Roche High growth indication Melanoma is a leading oncology growth indication Portfolio fit Opportunity to build a platform for personalized  medicine R&D footprint U.S. R&D presence in biotech Bay Area compliments  our global strategy  10
  12. 12. The San Francisco Bay Area Marin Solano Pharmaceutical Company Top-tier university San Francisco Contra Costa California is one of the most  Alameda active life‐science states in the  US San Mateo San Francisco Bay Area offers  Santa Cruz Santa Clara strong community of biotech,  and three world‐class  universities 11
  13. 13. About PLX4032 Initial target indication: metastatic melanoma    expressing the BRAF mutation Current stage: Phase III (BRIM3 trial) • An interim analysis of this Phase III showed the study met the   pre‐specified primary endpoint (OS & PFS) ( Plexxikon announced in 18 January, 2011) Development and commercialization partner: Roche Co‐developing diagnostic with Roche Molecular  Diagnostic Filing for EU and US marketing approval anticipated in  2011  12
  14. 14. Rights Obtained for PLX4032 Revenue is from running royalties Upon FDA approval, Daiichi Sankyo, Inc., will  co‐promote PLX4032 with Roche in the U.S. 13
  15. 15. Financial Conditions
  16. 16. Financial ConditionsDaiichi Sankyo has agreed with Plexxikon’s shareholders to acquire all shares of Plexxikon Daiichi Sankyo will pay US$805 million at closingDaiichi Sankyo will pay up to an additional US$130 million to current Plexxikon’s shareholders in milestone payments.Details of the financial calculation will be announced once finalized 15
  17. 17. Memo 15
  18. 18. Memo 15
  19. 19. Contact address regarding this material DAIICHI SANKYO CO., LTD. Corporate Communications Department TEL: +81-3-6225-1126Each numerical value regarding the future prospect in this material is derived from our judgmentand assumptions based on the currently available information and may include risk and uncertainty.For this reason, the actual performance data, etc. may differ from the prospective value. 19
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.